Ovarian Reserve Testing in Female Young Adult Cancer Survivors



Status:Recruiting
Conditions:Cancer, Cancer, Women's Studies, Infertility
Therapuetic Areas:Oncology, Reproductive
Healthy:No
Age Range:18 - 35
Updated:10/18/2018
Start Date:January 2011
End Date:December 2020
Contact:Samantha C Bailey
Email:ayastudy.ucsd@gmail.com
Phone:858-822-0768

Use our guide to learn which trials are right for you!

Young adult cancer survivors constitute an under served population to whom fertility
potential is particularly important. For female young adult patients, cancer treatment such
as alkylating chemotherapy are toxic to the finite number of eggs they have, resulting in
risks of infertility and premature menopause related to ovarian failure. Reproductive issues
are a major concern for young cancer survivors, but one that is understudied. Young cancer
survivors have few tools to measure post-treatment ovarian reserve, or the quantity and
quality of remaining eggs4. Accurate determination of ovarian reserve and fertility potential
would not only be an important research tool, but also directly impact clinical management.
The purpose of this study is to test if basal and provocative ovarian reserve testing can
predict return of menses in female young adult cancer survivors, to compare basal and
provocative ovarian reserve testing results between female young adult cancer survivors and
healthy controls, and to compare basal and provocative ovarian reserve testing results
between female young adult cancer survivors on and off of combined estrogen and progesterone
hormone products.

Participants will be asked to keep track of their periods over three months. If a participant
is taking birth control pills, patches, or vaginal ring, they will asked to come off the
birth control for 3 months. Participants will also be asked to undergo ovarian reserve
testing by blood draws and pelvic ultrasounds at the start and end of the 3 months.

Same as brief summary

Inclusion Criteria:

- Postmenarchal

- Cancer diagnosis

- Prior exposure to gonadotoxic therapy, inclusive of chemothearpy, pelvic or total body
irradiation, unilateral oophorectomy

- A minimum of 1 year since completion of gonoadotoxic therapy

- Intact uterus

- At least one ovary

Exclusion Criteria:

- Estrogen receptor positive cancers
We found this trial at
1
site
San Diego, California 91351
?
mi
from
San Diego, CA
Click here to add this to my saved trials